Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $101.4 million.

  • Agios Pharmaceuticals' Total Liabilities fell 3860.6% to $101.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.4 million, marking a year-over-year decrease of 3860.6%. This contributed to the annual value of $122.2 million for FY2024, which is 305.79% down from last year.
  • Agios Pharmaceuticals' Total Liabilities amounted to $101.4 million in Q3 2025, which was down 3860.6% from $101.7 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Total Liabilities ranged from a high of $191.8 million in Q1 2021 and a low of $89.0 million during Q1 2025
  • For the 5-year period, Agios Pharmaceuticals' Total Liabilities averaged around $128.5 million, with its median value being $126.1 million (2023).
  • In the last 5 years, Agios Pharmaceuticals' Total Liabilities tumbled by 6785.53% in 2021 and then soared by 3712.74% in 2024.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Total Liabilities stood at $145.8 million in 2021, then fell by 5.39% to $137.9 million in 2022, then decreased by 8.56% to $126.1 million in 2023, then decreased by 3.06% to $122.2 million in 2024, then decreased by 17.07% to $101.4 million in 2025.
  • Its Total Liabilities stands at $101.4 million for Q3 2025, versus $101.7 million for Q2 2025 and $89.0 million for Q1 2025.